SimBioSys
SimBioSys uses AI and biophysical simulations to create virtual replicas of individual tumors, enhancing precision cancer care.
Founded
2018SimBioSys uses AI and biophysical simulations to create virtual replicas of individual tumors, enhancing precision cancer care.
Founded in 2018 and headquartered in Champaign, IL, SimBioSys is a precision cancer care company dedicated to enhancing personalized and patient-specific understanding of cancer through advanced technology. The company's core mission is to redefine precision medicine and revolutionize patient care by leveraging artificial intelligence and biophysical simulations. Their flagship product, TumorScope, uses standard diagnostic data to create spatially resolved virtual replicas of individual tumors, enabling more precise treatment planning and addressing tumor heterogeneity.
Notable figures associated with SimBioSys include Tushar Pandey, the Chief Executive Officer. The company has garnered attention for its innovative approach to cancer treatment, attracting significant interest from investors in the life sciences sector. Key achievements include the successful deployment of TumorScope in clinical settings, demonstrating improved outcomes in personalized cancer care. Overall, SimBioSys is making a substantial impact on the field of oncology by providing tools that allow for more accurate diagnosis and tailored treatment strategies.
Companies similar to SimBioSys include Massive Bio, bioSyntagma, Elephas and OncoPrecision.
SimBioSys was founded in 2018.
SimBioSys' headquarters is located in Champaign, IL, US.
SimBioSys' most recent funding round was for $15M (USD) in October 2021.
As of Oct 26, 2021, SimBioSys has disclosed funding of $15M (USD). Undisclosed round amounts are excluded.
SimBioSys has 48 employees as of Feb 5, 2024.
OncoPrecision
oncoprecision.bio
